News | February 25, 2022
Risk appetite key to innovation in pharma and biopharma
Industry leaders discusses the need of innovation for the Indian drug industry at BioAsia 2022.
Industry leaders discusses the need of innovation for the Indian drug industry at BioAsia 2022.
It is a Phase 3 ready anti-myostatin adnectin for Spinal Muscular Atrophy (SMA).
The first wave of shipments includes several countries, such as Germany, France and Austria
Chandy was the president of the Industrial Division of Pall Corporation, a leading supplier of filtration, separation, and purification technologies. Previously, she was chief marketing officer at the Dow Chemical Company and Rohm and Haas Corporation
The Genome Valley region has played a pivotal role in fostering the life science industry and the state government has always supported its growth
Four additional AT2R agonists are expected to finalize preclinical evaluation during 2022
Haleon will have a portfolio of category-leading brands including Sensodyne, Voltaren, Panadol and Centrum
He will continue to lead business in LATAM and Asia regions in this new role
he financing was significantly oversubscribed with high demand from both existing and new investors.
Robust pipeline with around 50 projects in clinical development / cardiology portfolio poised for growth with launch products Kerendia (finerenone) and Verquvo (vericiguat)
Subscribe To Our Newsletter & Stay Updated
